Welcome to our dedicated page for Volitionrx news (Ticker: VNRX), a resource for investors and traders seeking the latest updates and insights on Volitionrx stock.
VolitionRx Limited develops epigenetics-based diagnostics through its Nucleosomics platform, which measures nucleosomes in blood and other bodily fluids. The company’s Nu.Q® product portfolio spans human diagnostics and monitoring for cancer, sepsis, trauma biomarker research and other disease areas, as well as veterinary oncology through Nu.Q® Vet assays.
VNRX news covers clinical publications and assay-development milestones, commercialization of Nu.Q® tests, veterinary cancer-test development, recombinant nucleosome products under rNuQ™, licensing and distribution activity, financial results, non-dilutive funding, equity financing and NYSE American listing-compliance matters. Volition’s research and development activities are centered in Belgium, with additional operations in the United States and London.
VolitionRx (NYSE AMERICAN: VNRX) announced its Q2 2024 financial results and business update. Key highlights include:
- Expanded access to Nu.Q® Vet Cancer Test to 17 countries
- Sold over 60,000 Nu.Q® Vet Cancer Tests in H1 2024, surpassing full-year 2023 sales
- Engaged in commercial discussions for potential licensing opportunities
- Q2 2024 revenue up 83% year-over-year at $396,000
- H1 2024 revenue up 55% year-over-year at $567,000
- Implemented cost reduction measures targeting $10 million in annualized savings
- Cash and cash equivalents of $6.0 million as of June 30, 2024
- Completed a $7 million registered direct offering with potential for additional $14.5 million
The company is focusing on securing its first licensing deal in the human space in H2 2024.
VolitionRx (NYSE AMERICAN: VNRX) has announced a registered direct offering of up to $21.5 million. The offering includes 12,727,273 shares of common stock (or equivalents) and milestone-linked warrants at $0.55 per share. H.C. Wainwright & Co. is the exclusive placement agent. The initial gross proceeds are expected to be $7 million, with potential additional proceeds of $14.5 million if all warrants are exercised. The offering is set to close around August 12, 2024. Funds will be used for research, product development, clinical studies, commercialization, and working capital. The offering is made under a shelf registration statement filed with the SEC.
VolitionRx (NYSE AMERICAN: VNRX) has announced a conference call scheduled for Thursday, August 15, 2024, at 8:30 a.m. U.S. Eastern Time to discuss its financial and operating results for the second quarter of 2024 and provide a business update. The call will be hosted by key executives including Louise Batchelor, Cameron Reynolds, Terig Hughes, and Dr. Andrew Retter. Participants can join via phone or listen to a live audio webcast on Volition's investor relations website. A replay of the call will be available until August 29, 2024. This event provides an opportunity for investors and analysts to gain insights into Volition's recent performance and future outlook.
VolitionRx (NYSE AMERICAN: VNRX), a multi-national epigenetics company, has enlisted PharmaVentures to provide strategic advice and support for licensing its oncology portfolio, including Nu.Q® Cancer and Capture-PCR™ technologies. The collaboration aims to secure licensing deals with industry leaders. Volition's technologies focus on simple, cost-effective blood-based assays to detect, guide treatment, and monitor cancer. Gael Forterre, Chief Commercial Officer of Volition, highlighted PharmaVentures' expertise in deal-making, while PharmaVentures' MD Adrian Dawkes expressed optimism about the potential of Volition's epigenetic technology to improve patient outcomes globally.
VolitionRx (NYSE AMERICAN: VNRX), a multi-national epigenetics company, has issued a mid-year review before its Annual Meeting on July 2, 2024. The review highlights the expansion of the Nu.Q® Vet Cancer Test to 15 countries, ongoing commercial discussions with major players in liquid biopsy, IVD, sepsis, and oncology, and preparation for potential near-term licensing opportunities. CEO Cameron Reynolds emphasized significant progress in 2024, including supporting veterinary partners and advancing Nu.Q® NETs for sepsis, Nu.Q® Lung Cancer, and Capture-PCR™ technologies toward licensing. With substantial study data nearing readiness, Volition aims to negotiate its first human-space licensing deal in the second half of 2024.
RedChip Companies will air interviews with Nexalin Technology (Nasdaq:NXL) and VolitionRX (NYSE American:VNRX) on the RedChip Small Stocks, Big Money™ show on Bloomberg TV, this Saturday, June 15, at 7 p.m. ET. Nexalin's CEO, Mark White, discusses their non-invasive neurostimulation technology for mental health conditions like insomnia, PTSD, and traumatic brain injuries. Volition's CEO, Cameron Reynolds, highlights their epigenetic markers for diagnostics, focusing on cancer and sepsis. Volition aims for cash flow neutrality by 2025 through non-dilutive funding, revenue growth, and cost reduction.
VolitionRx (NYSE AMERICAN: VNRX), a multi-national epigenetics firm, announced that its President and Group CEO, Cameron Reynolds, will present at the Jefferies Global Healthcare Conference in New York City on June 5, 2024, at 3:30 pm ET. The company aims to showcase its portfolio of patented epigenetic technologies for the early detection and monitoring of diseases such as sepsis and cancer. Investors are invited to schedule one-on-one meetings with the executive team by contacting investorrelations@volition.com.
VolitionRx (NYSE AMERICAN: VNRX) announced its Q1 2024 financial results and business update on May 13, 2024. Key highlights include $11.8 million in cash and cash equivalents, $170,000 in revenue (a 15% increase YoY), and ongoing cost reduction measures aiming for $10 million in annualized savings. The company is applying for $25 million in non-dilutive grants in the U.S. and $18 million in Europe. VolitionRx aims to achieve cash flow neutrality by 2025 through a mix of funding, revenue growth, and milestone payments. The company is focusing on commercializing its Nu.Q® NETs and Capture-PCR™ technologies, with new clinical data expected by the end of June 2024. A conference call to discuss these results is scheduled for May 14, 2024, at 8:30 a.m. U.S. Eastern Time.
VolitionRx (NYSE AMERICAN: VNRX) has scheduled a conference call on May 14, 2024, at 8:30 a.m. U.S. Eastern Time to discuss its financial and operating results for the first quarter 2024 and provide a business update. The call will be hosted by key executives and will include details on important events and upcoming milestones.
Summary not available.